Interactions of the HIV fusion inhibitor AR177 (ZINTEVIR) with the HIV type I second receptor

José A. Esté; Paul Proost; Sofie Struyf; A. Wuyts; Jo Van Damme; De Clercq Erik; Dominique Schols

doi:10.1016/s0166-3542(97)83141-5

Related publications

Article1997

Human immunodeficiency virus gp120 as the primary target of action of AR177 (Zintevir)

José A. Esté, Dominique Schols, Myriam Witvrouw, Peter Cherepanov, Christophe Pannecouque, Robert F. Rando, Zeger Debyser, Jan Desmyter, De Clercq Erik

Article1998

Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir)

José A. Esté, Cecilia Cabrera, Dominique Schols, Peter Cherepanov, Arantxa Gutiérrez, Myriam Witvrouw, Christophe Pannecouque, Zeger Debyser, Robert F. Rando, Bonaventura Clotet, Jan Desmyter, De Clercq Erik

Article1998

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

G A Donzella, Dominique Schols, Steven Lin, José A. Esté, Kirsten Nagashima, Paul J. Maddon, Graham P. Allaway, Thomas P. Sakmar, Geoffrey Henson, De Clercq Erik, John P. Moore

Article2023

<i>CXCR4 S338X</i> Promotes Resistance to Second Generation BTK Inhibitor and BCL-2 Inhibitor in WM Cells

Eleni Kalafati, Nefeli Mavrianou Koutsoukou, Alexandra Papadimou, Kostantina Taouxi, Meletios A Dimopoulos, Evangelos Terpos, Nicholas P. Anagnou, Efstathios Kastritis, Tina Bagratuni

Article2005

Blockade of SIV and HIV infection with CADA, a novel entry inhibitor that specifically targets the cellular CD4 receptor

Kurt Vermeire, Thomas W. Bell, Roger Le Grand, De Clercq Erik, Dominique Schols